Purpose: Primary objective was to determine response rate of patients with advanced pancreatic cancer to a novel lipoxygenase and thromboxane A2 synthetase inhibitor (CV6504); secondary objectives included estimation of pharmacokinetics of CV6504, target-enzyme inhibition, safety and tolerance, quality of life and survival.
Introduction
Pancreatic cancer is the fifth commonest cause of cancer death in the western world, with an incidence of 10 per 10 5 population in the UK. The overall five-year survival rate for patients with pancreatic cancer is less than 1% and there has been little improvement in survival in the last 20 years [1] . The only group of patients in whom the outlook is less gloomy is the minority of patients who have resectable disease at presentation, the five-year survival rate in those patients with negative resection margins is in the range 5%-36% [2, 3] . In a series of 13560 patients with pancreatic cancer from the West Midlands, only 2.6% underwent resection, with a fiveyear survival of 5.5% and an overall five-year survival of <0.2% [1] . Gudjonsson found much the same results in a review of the published literature and an analysis of patients from his own institution [4] .
Pancreatic-cancer patients also have a high incidence of cachexia. This cachexia may be so severe that it can become the patients' dominant symptom and may lead to death without vital organ involvement by tumour. This has led to the inclusion of a number of clinical end points indicative of anorexia and weight loss, when novel agents enter clinical trials in pancreatic cancer. Until very recently, despite the fact that many agents have been tried singly and in combination for the treatment of pancreatic cancer, the only one that has consistently shown to produce response rates in the region of 5%-15% is 5-FU [5, 6] . The results of treatment with 5-FU in advanced disease however have been disappointing, with no significant prolongation of survival and its use in this setting has never been universally recommended. Combination chemotherapy, e.g., with FAM, does not lead to any added benefit. Recent studies of a new chemotherapy agent (gemcitabine) in pancreatic cancer have been moderately encouraging. Two phase-II studies have been conducted in patients with advanced pancreatic cancer which showed that the drug had modest activity in the disease [7, 8] . In a randomised study comparing gemcitabine with bolus 5-FU, response rates of less than 10% were associated with symptom improvement in a validated quality-of-life measure and a small survival advantage for the gemcitabine treated group [9] . Recent studies with docetaxel suggest that it has a marginal objective response rate in patients with pancreatic cancer. However, the authors of this research believe that it may have an effect on reducing tumour growth rate leading to clinical benefit [10] .
Given the paucity of active drugs, there is a need for mechanistically novel anti-cancer agents in the treatment of pancreatic cancer. There is a growing body of evidence to suggest that arachidonic acid (AA) and its metabolites act as tumour promoters and increase cancercell proliferation rates. Lipoxygenases constitute a family of non-heme containing dioxygenases which catalyse conversion of AA ultimately to leukotrienes which have been associated with tumour progression in a variety of cancer model systems. CV6504 (HCI) (Figure 1) , is an inhibitor of 5-lipoxygenase and thromboxane A2 synthetase and is a scavenger of active oxygen species [11] . It has been shown to have anti-tumour activity against three established murine adenocarcinomas (MAC) which are refractory to standard cytotoxic agents. For the cachexia inducing MAC16 tumour, optimal anti-tumour activity was seen at dose levels of 10 to 25 mg/kg/day, together with a reversal of cachexia and a doubling of survival time. The remaining tumour fragments showed extensive necrosis in the regions distal from the blood supply. Growth of the MAC13 tumour was also effectively suppressed at dose levels between 5 and 50 mg/kg/day, resulting in a significant prolongation of survival. Growth of the MAC26 tumour was inhibited in a concentration-related manner, with doses of 25-50 mg/kg/day being optimal. Since the LD 50 for CV6504 in mice was 1.5 g/kg/day, the therapeutic index against all three tumours lay between 60 and 150. Anti-tumour activity against all three tumours at low-dose levels of CV6504 (10 mg/kg/day) was effectively supressed by concurrent administration of high doses of linoleic acid implying that inhibition of linoleate metabolism contributed to the anti tumour effect [12] .
CV6504 was developed initially as an anti-proteinuric agent and entered phase I clinical and pharmacokinetic studies in adult volunteers and patients with chronic glomerulonephritis. In summary, a dose of 300 mg daily in three divided doses, orally, was found to be well tolerated, rapidly absorbed, excreted (as a sulphate or glucoronide conjugate) in urine and reproducibly inhibited platelet activation and serum thromboxane B2 (Tx B 2 ) formation (Takeda Ltd, data on file). There was no clinical or pharmacodynamic evidence to suggest that further dose increments caused greater enzyme inhibition, therefore the dose of 100 mg TDS daily was selected on the basis of tolerability and demonstrable target-enzyme inhibition. Given its anti-cachexic effects a phase II trial was undertaken in patients with advanced pancreatic cancer with the following objectives: to determine if CV6504 has anti-cancer activity in patients with pancreatic cancer; to determine its toxicity and tolerance; to determine the pharmacokinetics and pharmacodynamic effects of CV6504.
Patients and methods

Eligibility
Patients with advanced histologically or cytologically-proven pancreatic cancer; WHO performance status of < 2; age > 18; measurable or assessable disease using UICC criteria; adequate haematological function at baseline (WBC > 4 x 1O 9 /1, platelets > 100 x 10 9 /l); adequate biochemical (renal, hepatic) function; (creatinine < upper limit normal; AST, ALT 4 2 x upper limit normal, bilirubin ^ upper limit of normal), a life expectancy of at least three months; patients must not have received chemotherapy within four weeks of enrolment (6 weeks if nitrosureas or mitomycin C). All patients gave written informed consent.
Dose schedule
Patients were treated on an out-patient basis and received 100 mg of CV6504 three times a day orally and remained on study until there was evidence of disease progression, excessive toxicity, patient refusal or withdrawal at the investigator's discretion. Patients were asked to avoid therapy with other drugs which might have anti-platelet properties, e.g., aspirin, non-steroidal agents and dipyridimole. To be considered eligible for assessment of efficacy, patients should have been dosed with CV6504 for a minimum of four weeks.
Disease assessment
Pre-treatment evaluation included a complete medical history and physical examination; a full blood count; a standard biochemical profile; CT scan of abdomen. During treatment, the patient attended every four weeks at which a full physical examination was performed. Blood counts and biochemistry were likewise repeated.
Patients had clinical measurements and scans performed every 12 weeks on trial to document the status of their disease. Clinical measurements were done within the week prior to the patient going on study. Radiological tests (CT scans or MRI) necessary for tumour measurement were done no more than two weeks prior to enrolling the patient into the study. Scans were repeated every three months. In the event of stable disease or response according to the standard UICC criteria, disease assessment was repeated at least four weeks after the initial date of response. All scans including patients with measurable and assessable disease were reviewed by external radiologists. Quality of life was assessed using validated instruments (Rotterdam Symptom Checklist and EORTC QLQ-C30 Version 2.0) every four weeks. A battery of anthropometric tests were performed by a trained member of the dietetic staff. These included weight, mid-arm muscle circumference and grip strength.
Pharmacokinetic (PK) and pharmacodynamic (PD) studies
Trough and peak (2 hours post dosing) samples for PK analysis were obtained at baseline, week 4 and at each 12-week visit. Blood was collected in a plain tube on ice, left to clot, centrifuged and then frozen within two hours of initial collection and stored at -20 °C, until analysis. CV6504 was measured using a sensitive and specific HPLC assay, with a co-efficient of variation of 2.5%-9.6% and detection limit of 3-15 ng/ml. Given the previous observation that a greatly increased dietary intake of linoleic acid in mice could abrogate the therapeutic effect of CV6504, linoleic acid was measured using a sensitive and specific GC-MS analytical system with a co-efficient of variation of 4.9% and a detection limit of < 1 ng/ml.
As CV6504 is a potent inhibitor of human thromboxane A 2 synthetase (IC50 = 0.3 urn), we measured plasma thromboxane B2 (TXB 2 ), a stable metabolite of thromboxane A2. Pre-and post-dose (2 hours) blood samples for assay of TXB2 were collected into EDTA tubes, centrifuged and stored at -20 °C until analysis. TXB2 was measured using a commercially-available enzyme-immunoassay system, 'Biotrak', as supplied by Amersham Life Science. The plasma was acidified using 6N HC1 and extracted on Amprep C2 100 mg columns. Following drying and resolubilization in phosphate buffer (pH 7.5) samples were analysed in duplicate forTXB 2 levels. The coefficient of variation for the 'Biotrak' assay system calculated from paired duplicates was 4.6% and the limit of detection was 3.6 pg/ml.
Statistical methods
Time to tumour progression was estimated from study entry (date of first dose of study medication) to documented progression of disease and overall survival was measured from study entry until death. Nonparametric survival probabilities were estimated by the method of Kaplan-Meier. Comparisons between groups of patients categorise according to their baseline plasma-peak levels of CV6504 and its conjugates and height-to-weight ratio were performed using the Wilcoxon Rank Sum Test. The peak-plasma levels of CV6504 and conjugates were correlated with peak-plasma levels of thromboxane using Spearman's Correlation Coefficient.
Sample size was based on a "success' proportion threshold of 20% as the preset minimum-response rate to CV6504 (HC1) considered worthy of further study. Using a two-stage Bayesian design, 14 patients were to be evaluated in the 1st stage, and in the event that at least 1 'success' was observed then a further 11 patients were to be evaluated, otherwise the study would be terminated. To be considered assessable for toxicity the patient needed to receive at lease one dose of study medication and for response evaluation, receive at least four weeks treatment.
Overall response was assessed as 'success' or 'failure' using conventional UICC criteria: 'success' (partial response, complete response, or stable disease after 12 weeks or more of treatment); 'failure' (progression within the first 12 weeks of treatment).
Results
Patient characteristics
These are summarised in Table 1 . Thirty-one patients were entered in the trial (15 male, 16 female), with a mean age of sixty-two years, (± 10.4, SD) and a medianperformance status of one (range 0-2). Two of the patients had received prior chemotherapy.
Efficacy
Eight patients were excluded from the efficacy analysis; seven patients had less than twenty-eight days medication, (4 due to treatment non-compliance; 3 withdrawn due to leg pain which was scored moderate but patients refused further therapy following resolution of side effects) and one patient had no baseline CTscan.
For those patients considered eligible for assessment of efficacy (n = 23) there were no complete or partial responses, 10 patients with stable disease and 13 patients had progressed at the three-month disease reassessment point. Therefore 10 of 31 patients (32%) achieved stable disease. According to the protocol design, there were, therefore, 10 'successes'and 13 'failures'. The median time to disease progression for evaluable patients (n -23) was 89 days. For 'successful' patients, it was 337 days but this is likely to be an over estimate due to variability of data and small sample size. Median survival for patients considered eligible for assessment of efficacy is 36.6 weeks (95% confidence interval: 20.9-51.4 weeks). None of the patients in this trial received chemotherapy or other experimental agents on disease progression.
Toxicity profile
CV6504 was well tolerated, in general terms and had no serious side effects. It can often be difficult to separate drug-associated adverse events from those related to the disease itself, particularly in a symptomatic group of Table 3 . Correlation between average plasma levels of CV6504 (and its major metabolites G-glucoronide S-sulphate) and % inhibition of thromboxane B2 synthesis for patients with stable disease (group 1) and those with progressive disease (group 2). patients with advanced disease. There was none of the toxicity associated with conventionally cytotoxic drugs, i.e., no myelosuppression, mucositis, alopecia. Five patients suffered moderate-cramping myalgia affecting both legs (calf region) which recovered completely within the days following drug withdrawal, and did not recur in the two patients who restarted treatment. Analgesics were not used therefore there is no information as to whether co-administration of pain killers would have reduced the pain and prevented drug discontinuation.
Quality of life scores
The quality of life and anthropometric data are not shown, however there is wide inter-individual variation in the data. A moderate improvement was observed in most of the functional scales of the EORTC QoL questionnaire. Also, an improvement in the symptomatology and problem domains were generally seen in the symptom scale and items. Similarly, WHO performance status (PS) was scored for each patient at monthly intervals with all patients having a PS of 0-2 at initiation, but as the study progressed, the proportion of patients in each PS group remained approximately constant, and was similar for patients with stable and progressive disease. The anthropometric data suggest that body-mass index, grip strength and mid-arm inside circumference are stable and well-maintained in patients who went on to complete the 12-week study period. Mean weight on study entry was 64.6 ± 14.3 kg and was well maintained for the 12 weeks of the study period (67.4 ± 10.9 kg).
Pharmacokinetic and pharmacodynamic studies
The average plasma levels for CV6504 and its major metabolites and their relationship to the duration of oral dosing, are summarised in Table 2 . There is no significant variation or accumulation with time. Similarly, plasma linoleic-acid levels measured simultaneously showed little change throughout the study period and were well below (3 orders of magnitude) the levels which reversed the efficacy of CV6504 in mice. Table 3 provides a more detailed view of average plasma concentrations of CV6504, its metabolites and their relationship to the degree of inhibition of TBX2 synthesis. Patients were divided into those who had stable disease at three months (group 1) or those who progressed at or before three months therapy (group 2). There are no statistically significant differences comparing any of these parameters between both groups (Wilcoxon rank sum test) and there is no correlation between average drug concentrations and the degree of inhibition of TBX2 synthesis (Spearman Rank Correlation Coefficient). When patients were stratified according to their baseline peak plasma level above or below the baseline mean peak plasma levels of CV6504, across all evaluable patients, there was no statistically-significant difference between the two groups of patients for CV6504 (P = 0.071). The estimated probabilities of disease progression within 12 weeks were 0.69 for patients with a baseline peak plasma level below the mean peak plasma level and 0.40 for patients with a baseline plasma level above the mean peak plasma level. The same analysis conducted for the conjugates of CV6504 did not indicate any statistically significant differences between the two groups of patients, P = 0.28 (CV6504-S), P -0.90 (CV6504-G).
Discussion
Conventional approaches to the treatment of pancreatic cancer have met with rather limited success, hence the need to develop novel therapeutic agents. CV6504 is a potent and specific inhibitor of 5-lipoxygenase and thromboxane A2 synththetase, enzymes thought to be involved in signal transduction of cancer-cell proliferation. It has shown impressive preclinical anti-tumour and anti-cachectic activity in a range of models. CV6504 was initially developed as an anti-proteinuric agent and entered clinical trial in normal volunteers and patients with glomerulonephritis, so it has had an unusual development pathway for an anti-neoplastic drug. Rather than the usual route of escalating to the maximum tolerated dose and selecting a schedule close to this to go forward to phase II, CV6504 was dosed to produce significant inhibition of thromboxane A2 synthetase, using the drop in plasma TBX2 from baseline as a surrogate of enzyme inhibition. This would seem a more rational way of identifying appropriate dose-schedules for signal-transduction inhibitors which, as cytostatic agents, would be more effective if administered continuously rather than the intermittent schedules common to cytotoxic drugs [13] [14] [15] [16] . In addition, certain signal transduction inhibitors have been shown to have bellshaped dose-response curves, implying that more is not necessarily better.
In the present trial, CV6504 was well tolerated, had no serious side effects, caused moderate cramping myalgia affecting both legs, and did not induce any of the toxicities normally associated with conventional chemotherapeutic drugs, such as alopecia, myelosuppression and mucositis. There were no conventional responses, but 43% of patients had stable disease three months after initiation of therapy. Advanced pancreatic cancer is notoriously difficult to assess radiologically and response rate can be criticised as a relevant endpoint, therefore survival curve analysis is important. The one-year survival rate of about 25% is reasonable for patients with this sort of tumour burden, but clearly represents a selected group and must be viewed with caution.
Quality of life and performance status were well maintained in those patients who continued therapy. Grip strength, mid arm-muscle circumference were steady throughout treatment, implying an anti-cachectic effect. Body weight remained steady well beyond the study period of 12 weeks until week 32. Clearly this could only truly be demonstrated in a randomised trial.
It has become increasingly common to find phase II trials in which pharmacokinetic parameters are related to side effects and response rates. This study presented the opportunity to correlate clinical endpoints of toxicity and efficacy with the drug's pharmacokinetics and pharmacodynamics. The range of plasma concentrations of the parent compound and its dominant glucoronide and sulphate metabolites are similar to those reported in the normal volunteer studies (CV6504 Investigator Brochure, Takeda Ltd). There was no apparent accumulation of drug in plasma with prolonged dosing, or shift in the pattern of metabolism. The fall in plasma TBX2 from a pretreatment baseline in response to therapy was used as a measure of the degree of inhibition of thromboxane A2 synthetase. On average, there was 75% inhibition of the enzyme, which was maintained for the duration of therapy. There was no apparent correlation between steady-state plasma levels of CV6504 and the degree of enzyme inhibition, both of which were similar in patients with stable or progressive disease. The plasma concentration of parent drug achieved (approximately 0.07 uM) was significantly lower than the reported IC 50 concentrations for 5-lipoxygenase and thromboxane A2 synthetase (0.3-0.4 uM). However, it is possible that drug could be more concentrated in tissue than plasma, and although the enzyme-inhibitory activity of the glucoronide and sulphate metabolites is unknown, they could possibly be contributing to its mechanism of action. One other factor is that it could be worthwhile dose escalating CV6504 to extend exploration of its dose-response relationship in cancer patients.
In summary, CV6504 would appear to stabilise disease in about 32% of patients with advanced pancreatic cancer. There is not a clear relationship between stabilisation of disease by CV6504 and its pharmacokinetics or surrogate markers of biochemical activity, in this relatively small patient sample. Nevertheless it is well tolerated and could be combined with conventional chemotherapeutic agents without compromising on individual dose of CV6504 or the cytotoxic drug, in factorialised clinical trials.
